Fetax interlaboratory validation study: Phase II testing

1994 ◽  
Vol 13 (10) ◽  
pp. 1629-1637 ◽  
Author(s):  
Angela M. Gaudet-Hull ◽  
James R. Rayburn ◽  
John A. Bantle ◽  
Dennis T. Burton ◽  
Steven D. Turley ◽  
...  
Keyword(s):  
Phase Ii ◽  
Validation Study ◽  
Study Phase ◽  
Interlaboratory Validation

FETAX INTERLABORATORY VALIDATION STUDY: PHASE II TESTING

1994 ◽  
Vol 13 (10) ◽  
pp. 1629 ◽  
Author(s):  
John A. Bantle ◽  
Dennis T. Burton ◽  
Douglas A. Dawson ◽  
James N. Dumont ◽  
Robert A. Finch ◽  
...  
Keyword(s):  
Phase Ii ◽  
Validation Study ◽  
Study Phase ◽  
Interlaboratory Validation

scholarly journals Commercial Motor Vehicle Driving Simulator Validation Study: Phase II

2011 ◽  
Author(s):  
Justin F. Morgan ◽  
Scott A. Tidwell ◽  
Alejandra Medina ◽  
Myra Blanco ◽  
Jeffrey S. Hickman ◽  
...  
Keyword(s):  
Phase Ii ◽  
Validation Study ◽  
Driving Simulator ◽  
Motor Vehicle ◽  
Study Phase ◽  
Vehicle Driving Simulator ◽  
Commercial Motor Vehicle ◽  
Motor Vehicle Driving

FETAX Interlaboratory Validation Study: Phase III-Part 1 Testing

1996 ◽  
Vol 16 (6) ◽  
pp. 517-528 ◽  
Author(s):  
John A. Bantle ◽  
Robert A. Finch ◽  
Dennis T. Burton ◽  
Douglas J. Fort ◽  
Douglas A. Dawson ◽  
...  
Keyword(s):  
Validation Study ◽  
Phase Iii ◽  
Study Phase ◽  
Interlaboratory Validation

Open Scenario Study, Phase II Report: Assessment and Development of Approaches for Satisfying Unclassified Scenario Needs

2010 ◽  
Author(s):  
Jason A. Dechant ◽  
James S. Thomason ◽  
Ylli Bajraktari ◽  
Mary C. Flythe ◽  
Anthony C. Hermes ◽  
...  
Keyword(s):  
Phase Ii ◽  
Study Phase ◽  
Scenario Study

Condensing Heat Exchanger Microbial Growth and Control Study-Phase II

1993 ◽  
Author(s):  
Robert W. Marsh ◽  
Mark E. Caron ◽  
Carol Metselaar ◽  
John Steele
Keyword(s):  
Heat Exchanger ◽  
Phase Ii ◽  
Microbial Growth ◽  
Study Phase ◽  
Condensing Heat Exchanger ◽  
And Control ◽  
Control Study

Determination of Oxadixyl in Wines by Liquid Chromatography-Tandem Mass Spectrometry: Single-Laboratory and Interlaboratory Validation Study

2014 ◽  
Vol 97 (6) ◽  
pp. 1701-1706
Author(s):  
Armen Mirzoian ◽  
Jeffrey R Ammann
Keyword(s):  
Validation Study ◽  
High Throughput Screening ◽  
Multiple Reaction Monitoring ◽  
Direct Injection ◽  
Ionization Source ◽  
Minimal Sample ◽  
The Matrix ◽  
Liquid Chromatography Tandem Mass ◽  
Interlaboratory Validation

Abstract A direct injection LC/MS/MS method for the determination of the pesticide oxadixyl in wines was developed and validated. A sample divert valve was used to deliver the fraction that contained oxadixyl to the mass spectrometer's electrospray ionization source. Oxadixyl was monitored and quantitated using two transitions in multiple reaction monitoring mode. The method demonstrated recoveries of 99.2 ± 2.0 and 96.7 ± 5.2% for red and white wines, respectively, a linearity range of 2–20 μg/L, LOD at 0.7 μg/L, LOQ of 2.0 μg/L, and precision values of 8.2% (RSDr) and 6.2% (RSDR). Direct injection of the wine onto a C18 ultra-performance LC column allowed automation and high throughput screening. Benefits of this approach include minimal sample preparation, short (3 min) run times, and the use of matrix-matched calibration standards, which minimize the matrix effect due to interferences from wine phenolics, sugars, and various other components. The method's performance characteristics were not statistically different for white and red wines. An additional interlaboratory validation study involved 12 laboratories and demonstrated good data agreement with HorRat values ranging from 0.23 to 0.52.

scholarly journals Influence of Renin-Angiotensin System Inhibitors on Lower Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

2020 ◽  
Author(s):  
Timothy M E Davis ◽  
Wendy A Davis
Keyword(s):  
Type 2 Diabetes ◽  
Respiratory Tract ◽  
Phase Ii ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Study Phase ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections

Objective:<b> </b>To determine whether<b> </b>angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) protect against lower respiratory tract infections complicating type 2 diabetes. <p>Research design and methods:<b> </b>Of 1,732 participants with diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011, 1,482 had confirmed type 2 diabetes (mean age of 65.8 years, 51.6% were males, median diabetes duration 9.0 years). All were followed for hospitalizations for/with, or deaths from, pneumonia/influenza ascertained from validated administrative data linkage from study entry to end-2016. Cox and competing risk regression were used to identify independent predictors of this outcome.</p> <p>Results:<b> </b>Two-thirds of participants (n=982) were taking an ACEi and/or ARB at study entry (498 (33.6%) ACEi, 408 (27.5%) ARB, 76 (5.1%) both).<b> </b>During 9,511 person-years of follow-up (mean 6.4±2.0 years), 174 participants had incident pneumonia/influenza (156 hospitalizations, 18 deaths without hospitalization). In Cox regression analysis, baseline ACEi/ARB use was independently associated with a reduced risk of incident pneumonia/influenza (cause-specific hazard ratio (HR) (95% confidence interval) 0.64 (0.45, 0.89), <i>P</i>=0.008). Allowing for the competing risk of death did not change this finding (subdistribution HR 0.67 (0.48, 0.95), <i>P</i>=0.024), and similar reductions were seen for ACEi, ARB alone, and ACEi/ARB combination therapy. There was no significant change in use of ACEi/ARB during follow-up (interaction with ln(time), <i>P</i>=0.70). Other significant predictors of incident pneumonia/influenza were previously reported, clinically plausible variables.</p> <p>Conclusions:<b> </b>ACEi/ARB reduce the risk of pneumonia/influenza in community-based people with type 2 diabetes.<b><br> </b></p>

Sign in / Sign up

Export Citation Format

Share Document